Company: AZN
Filing Date: 2025-03-17
Form Type: 6-K
Source: 0001654954-25-002841
Chunk: 3

Company: ASTRAZENECA PLC
Filing Date: 2025-03-17
Form: 6-K
Chunk 3
---
 medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca .

#### Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

#### References
1. Bilezikian JP. Hypoparathyroidism. J Clin Endocrinol Metab . 2020;105(6):1722-1736. doi:10.1210/clinem/dgaa113.

2. Vadiveloo T, et al. A population-based study of the epidemiology of chronic hypoparathyroidism. J Bone Miner Res. 2018;33(3):478-485.

3. Villarroya-Marquina I, et al. Influence of gender and women's age on the prevalence of parathyroid failure after total thyroidectomy for multinodular goiter. Gland Surg. 2020;9(2):245-251.

4. Deering KL, et al. Economic burden of patients with post-surgical chronic and transient hypoparathyroidism in the United States examined using insurance claims data. Orphanet J Rare Dis . 2024;19(1):164.

5. Gafni RI, Collins MT. Hypoparathyroidism. N Engl J Med . 2019;380(18):1738-1747. doi:10.1056/NEJMcp1800213

6. Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab . 2016;101(6):2300-2312. doi:10.1210/jc.2015-3909

7. Clarke BL, et al. Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab . 2016;101(6):2284-99.

8. Abate EG, et al. Review of hypoparathyroidism. Front Endocrinol (Lausanne). 2017;7:172.

9. ClinicalTrials.gov. Evaluation of the safety and efficacy of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (CALYPSO). NCT Identifier: N